

FIRST AMENDMENT AND RESPONSE
U.S.S.N. 10/754,456
Attorney Docket No. 13139-0104 (13721.105006)

RECEIVED
CENTRAL FAX CENTER
MAR 08 2007

Amendments to the Claims:

Please amend Claims 1, 16-18, and 20. This listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of increasing an immune response to a target in an individual comprising, administering to the individual an effective amount of a composition comprising one or more immunity linkers, wherein the immunity linkers molecules comprise at least one first binding site and at least one second binding site, wherein the second binding site is an aptamer nucleic acid, wherein the second binding site binds to the target, wherein the individual has a pre-existing immune response to the first binding site, ~~or an immunological equivalent thereof~~, and wherein the immune response is selected from a cellular immune response, and a humoral immune response, and an innate immune response.

2. (Previously Presented) The method of Claim 1, wherein the pre-existing immune response is induced by administering to the individual a universal immunogen comprising the first binding site.

3. (Previously Presented) The method of Claim 1, wherein the pre-existing immune response is induced by administering to the individual a universal immunogen that is an immunological equivalent of the first binding site.

4. (Previously Presented) The method of Claim 1, wherein the pre-existing immune response exists in the individual without administration of a universal immunogen.

5. Canceled.

6. Canceled.

7. (Previously Presented) The method of Claim 1, wherein the target is a pathogen.

8. Canceled.

9. Canceled.

FIRST AMENDMENT AND RESPONSE
U.S.S.N. 10/754,456
Attorney Docket No. 13139-0104 (13721.105006)

10. Canceled.
11. Canceled.
12. Canceled.
13. (Previously Presented) The method of Claim 1, wherein the individual is unable to mount an effective immune response to the target prior to administration of the immunity linker.
14. (Previously Presented) The method of Claim 1, wherein the immune response is a cellular immune response.
15. (Previously Presented) The method of Claim 1, wherein the immune response is a humoral immune response.
16. (Currently Amended) The method of Claim 1, wherein the composition comprises one or more ~~a population of different~~ immunity linkers wherein the comprising first binding sites that differ in
 - a. their specificity for different epitopes on the immune response component,
or
 - b. their affinity for the same epitopes on the immune response component.
17. (Currently Amended) The method of Claim 16, wherein the immune response components comprise[[s]] an antibody.
18. (Currently Amended) The method of Claim 1, wherein the composition comprises one or more ~~a population of different~~ immunity linkers comprising second binding sites that differ in
 - a. their specificity for different epitopes on the target, or
 - b. their affinity for the same epitope on the target.
19. Canceled.

FIRST AMENDMENT AND RESPONSE

U.S.S.N. 10/754,456

Attorney Docket No. 13139-0104 (13721.105006)

20. (Currently Amended) A method of increasing a humoral immune response to a target in an individual comprising, administering to the individual an effective amount of a composition comprising one or more immunity linkers, wherein the linkers comprise at least one first binding site and at least one second binding site, wherein the first binding site binds to a humoral immune response component, ~~or an immunological equivalent thereof,~~ wherein the second binding site is an aptamer nucleic acid, wherein the second binding site binds to the target, and wherein the target normally elicits a cellular immune response in that or another individual.

21. (New) The method of Claim 1, wherein the immune response is an innate immune response.